https://ir.iovance.com/news-releases/news-release-details/iovance...

https://ir.iovance.com/news-releases/news-release-details/iovances-amtagvitm-lifileucel-receives-us-fda-accelerated

AMTAGVI is the first and the only one-time, individualized T cell therapy to receive FDA approval for a solid tumor cancer. The proposed mechanism for AMTAGVI offers a new cell therapy approach that deploys patient-specific T cells called TIL cells. When cancer is detected, the immune system creates TIL cells to locate, attack, and destroy cancer. TIL cells recognize distinctive tumor markers on the cell surface of each person’s cancer. When cancer develops and prevails, the body’s natural TIL cells can no longer perform their intended function to fight cancer.

AMTAGVI is manufactured using a proprietary process to collect and expand a patient’s unique T cells from a portion of their tumor. AMTAGVI returns billions of the patient’s T cells back to the body to fight their cancer.* Authorized Treatment Centers (ATCs) will administer AMTAGVI to patients as part of a treatment regimen that includes lymphodepletion and a short course of high-dose PROLEUKIN^® (aldesleukin).

https://www.fiercepharma.com/pharma/national-resilience-teams-md-anderson-adding-new-cell-therapy-plant-its-bustling

https://www.biospace.com/article/an-fda-approval-for-iovance-could-jumpstart-40-year-old-field-/

“TIL, which is a cell therapy, offers the potential of long-term curative responses, which small molecules haven’t,” for melanoma patients, said Jason Bock, CEO of CTMC, a joint venture between biotech Resilience and MD Anderson Cancer Center. Lifileucel will be especially important for the nearly 50% of patients for whom checkpoint inhibitors have not worked, Bock told BioSpace.

Interesting to see that our SAB VP has positioned herself as a director of CTMC. It was stated in the last Qtrly that CellPryme was being evaluated by a third party with a commercial therapy (or words to that effect). So, our "former" collaborators, MD Anderson and Thermo Fisher are in the mix.